99mTc-cAbVCAM1-5 Imaging Is a Sensitive and Reproducible Tool for the Detection of Inflamed Atherosclerotic Lesions in Mice
暂无分享,去创建一个
Gilles Barone-Rochette | Daniel Fagret | Catherine Ghezzi | Mitra Ahmadi | Nick Devoogdt | Tony Lahoutte | Alexis Broisat | Pascale Perret | Jakub Toczek | Laurent S Dumas | Sandrine Bacot | Lotfi Slimani | Audrey Soubies | Laurent M Riou | Jakub Toczek | P. Perret | N. Devoogdt | G. Barone-Rochette | A. Broisat | L. Riou | M. Ahmadi | T. Lahoutte | D. Fagret | C. Ghezzi | L. Slimani | S. Bacot | A. Soubies | Laurent S. Dumas
[1] Z. Fayad,et al. Imaging Atherosclerosis and Vulnerable Plaque , 2010, Journal of Nuclear Medicine.
[2] Marleen Keyaerts,et al. Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer , 2013, The Journal of Nuclear Medicine.
[3] Han Liu,et al. Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis , 2009, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
[4] G. Moneta,et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .
[5] V. Fuster,et al. Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin. , 2012, JACC. Cardiovascular imaging.
[6] B. Kaufmann,et al. Noninvasive Ultrasound Molecular Imaging of the Effect of Statins on Endothelial Inflammatory Phenotype in Early Atherosclerosis , 2013, PloS one.
[7] V. Fuster,et al. The year in atherothrombosis. , 2004, Journal of the American College of Cardiology.
[8] M. Davies,et al. The expression of the adhesion molecules ICAM‐1, VCAM‐1, PECAM, and E‐selectin in human atherosclerosis , 1993, The Journal of pathology.
[9] S. Micuda,et al. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. , 2008, Life sciences.
[10] Jakub Toczek,et al. Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions , 2012, Circulation research.
[11] E. Boerwinkle,et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.
[12] C. Alpers,et al. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. , 1996, Circulation.
[13] M. Farkouh,et al. Emerging anti-inflammatory drugs for atherosclerosis , 2013, Expert opinion on emerging drugs.
[14] Ralph Weissleder,et al. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. , 2009, JACC. Cardiovascular imaging.
[15] Ralph Weissleder,et al. The Vascular Biology of Atherosclerosis and Imaging Targets , 2010, Journal of Nuclear Medicine.
[16] P. Barter,et al. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk , 2012, Journal of Lipid Research.
[17] R. Ross,et al. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[18] V. Fuster,et al. Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. , 2011, JACC. Cardiovascular imaging.
[19] P. Libby,et al. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). , 2011, American heart journal.
[20] M. Ferguson,et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. , 1993, The Journal of clinical investigation.
[21] Ralph Weissleder,et al. Noninvasive Vascular Cell Adhesion Molecule-1 Imaging Identifies Inflammatory Activation of Cells in Atherosclerosis , 2006, Circulation.
[22] H. Drexler,et al. Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis. , 2005, Atherosclerosis.
[23] Zahi A Fayad,et al. Atherothrombosis and high-risk plaque: part I: evolving concepts. , 2005, Journal of the American College of Cardiology.
[24] J. Jukema,et al. Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels. , 2011, Atherosclerosis.
[25] C. Ballantyne,et al. Pharmacological strategies for lowering LDL cholesterol: statins and beyond , 2011, Nature Reviews Cardiology.
[26] Z. Fayad,et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. , 2013, Journal of the American College of Cardiology.
[27] P. Libby,et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. , 2013, American heart journal.
[28] M. Abrar,et al. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake , 2011, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
[29] J. H. Rudd,et al. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. , 2012, JACC. Cardiovascular imaging.
[30] Takashi Kato,et al. Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] V. Fuster,et al. The year in atherothrombosis. , 2013, Journal of the American College of Cardiology.
[32] Antonio Colombo,et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. , 2003, Circulation.
[33] P. Hansen,et al. Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. , 2001, The Biochemical journal.